Related Experiment Video
Updated: Apr 11, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.3K
Type 2 diabetes drugs: a review.
Barbara Freeland1, Margo S Farber
1Barbara Freeland, DNP, RN, ACNS-BC, CDE, is a Clinical Assistant Professor, School of Nursing, University of Michigan, Ann Arbor, Michigan. Margo S. Farber, PharmD, is a Director, Drug Information Service, University of Michigan Health System, Ann Arbor, Michigan.
Home Healthcare Now
|June 3, 2015
Summary
New diabetes drugs target multiple metabolic issues in Type 2 diabetes. Understanding these medications helps clinicians guide patients toward better glucose control and self-care.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus is a prevalent condition among home care patients.
- Type 2 diabetes involves complex metabolic dysfunctions.
Purpose of the Study:
- To review the variety of available diabetes medications.
- To assist clinicians in patient self-care guidance for optimal glucose control.
Main Methods:
- Literature review of current diabetes pharmacotherapies.
- Analysis of drug mechanisms targeting metabolic defects.
Main Results:
- A wide array of medications targeting Type 2 diabetes metabolism is available.
- These drugs offer diverse approaches to managing hyperglycemia.
Conclusions:
- Understanding the pharmacological options is crucial for effective diabetes management.
- Clinician guidance on medication and self-care promotes better patient outcomes.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
5.8K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.8K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
981
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
981
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
01:06Oral Hypoglycemic Agents: Glinides
981
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
981
01:22Diabetes Mellitus: Overview and Type I Subtype
6.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.3K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K